A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Basic science
Enrollment
48estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-27 | actual | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-1042
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events
measured Up to approximately 32 days
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
measured Up to approximately 3 days
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
measured Up to approximately 3 days
Number of Participants with Abnormal Change in Physical Examinations
measured Up to approximately 3 days
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
measured Up to approximately 3 days
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
measured Up to approximately 3 days
Maximum Plasma Concentration (Cmax) of ABBV-1042
measured Up to approximately 3 days
Time to Cmax (Tmax) of ABBV-1042
measured Up to approximately 3 days
Apparent terminal phase elimination constant (β) of ABBV-1042
measured Up to approximately 3 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1042
measured Up to approximately 3 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1042
measured Up to approximately 3 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1042
measured Up to approximately 3 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed